Actively Recruiting
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Led by Dartmouth-Hitchcock Medical Center · Updated on 2026-05-05
36
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
CONDITIONS
Official Title
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Post-menopausal women with ER+ breast cancer
- Metastatic or locoregional recurrence not curable with intent to cure
- Received at least 1 prior endocrine-based therapy in the advanced or metastatic setting
You will not qualify if you...
- No concurrent anti-cancer therapies allowed during 17b-estradiol treatment, except trastuzumab for HER2+ history and anti-resorptive bone therapies
- Received investigational cancer therapy within the last 3 weeks
- Known central nervous system disease unless stable for 3 months or more
- History of deep venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, or congestive heart failure
- Previous malignancy not treated with curative intent or with estimated recurrence risk of 30% or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
Research Team
R
Research Nurse
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here